EMEA-001577-PIP03-17

Table of contents

Key facts

Invented name
Descovy
Active substance
  • emtricitabine
  • tenofovir alafenamide
Therapeutic area
Infectious diseases
Decision number
P/0139/2018
PIP number
EMEA-001577-PIP03-17
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Prevention of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Gilead Sciences International Ltd

E-mail: regulatory.pip@gilead.com
Tel. +44 (0)1223 897300

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number
EMEA-C-001577-PIP03-17
Compliance opinion date
20/09/2019
Compliance outcome
positive

Decision

Related content

How useful was this page?

Add your rating